TY - JOUR
T1 - Efficacy of rabbit antithymocyte globulin as first-line treatment of severe aplastic anemia
T2 - an Asian multicenter retrospective study
AU - Chuncharunee, Suporn
AU - Wong, Raymond
AU - Rojnuckarin, Ponlapat
AU - Chang, Cheng Shyong
AU - Chang, Kian Meng
AU - Lu, Meng Yao
AU - Hwang, Wen Li
AU - Koh, Liang Piu
AU - Chen, Tsai Yun
AU - Leung, Anskar Yh
AU - Norasetthada, Lalita
AU - Wang, Shih Chung
AU - Chang, Ming Chih
AU - Wu, Kang Hsi
AU - Issaragrisil, Surapol
N1 - Funding Information:
Dr. Rojunuckarin has received research funding from Sanofi. All other authors have no relevant financial relationships to disclose.
Publisher Copyright:
© 2016, The Japanese Society of Hematology.
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Due to the unavailability of horse antithymocyte globulin (ATG) in many markets worldwide, patients with severe aplastic anemia (SAA) are limited to the use of rabbit ATG. We aimed to analyze hematologic response and overall survival (OS) of Asian patients treated with rabbit ATG as first-line therapy of SAA. We retrospectively reviewed the medical records of 97 consecutive patients who received rabbit ATG as first-line treatment of SAA from 2006 to 2012 at centers in four Asian countries. The primary endpoint was 6- and 12-month overall response rates (ORR) for patients receiving rabbit ATG within the recommended dose range (2.5–3.75 mg/kg/day). Secondary endpoints included ORR in patients receiving any dose of rabbit ATG and 2-year OS. For patients who received rabbit ATG within the recommended dose range, 6- and 12-month ORRs were 17.4 and 63.6 %, respectively. For patients who received any dose of rabbit ATG, 6- and 12-month ORRs were 24.3 and 68.6 %, respectively. The 2-year OS rate was 86.3 %. Rabbit ATG is effective for treatment of SAA in Asian patients. The 12-month ORR and 2-year OS with rabbit ATG were comparable to historical results obtained with horse ATG.
AB - Due to the unavailability of horse antithymocyte globulin (ATG) in many markets worldwide, patients with severe aplastic anemia (SAA) are limited to the use of rabbit ATG. We aimed to analyze hematologic response and overall survival (OS) of Asian patients treated with rabbit ATG as first-line therapy of SAA. We retrospectively reviewed the medical records of 97 consecutive patients who received rabbit ATG as first-line treatment of SAA from 2006 to 2012 at centers in four Asian countries. The primary endpoint was 6- and 12-month overall response rates (ORR) for patients receiving rabbit ATG within the recommended dose range (2.5–3.75 mg/kg/day). Secondary endpoints included ORR in patients receiving any dose of rabbit ATG and 2-year OS. For patients who received rabbit ATG within the recommended dose range, 6- and 12-month ORRs were 17.4 and 63.6 %, respectively. For patients who received any dose of rabbit ATG, 6- and 12-month ORRs were 24.3 and 68.6 %, respectively. The 2-year OS rate was 86.3 %. Rabbit ATG is effective for treatment of SAA in Asian patients. The 12-month ORR and 2-year OS with rabbit ATG were comparable to historical results obtained with horse ATG.
UR - http://www.scopus.com/inward/record.url?scp=84976908629&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84976908629&partnerID=8YFLogxK
U2 - 10.1007/s12185-016-2053-8
DO - 10.1007/s12185-016-2053-8
M3 - Article
C2 - 27376944
AN - SCOPUS:84976908629
SN - 0925-5710
VL - 104
SP - 454
EP - 461
JO - International Journal of Hematology
JF - International Journal of Hematology
IS - 4
ER -